TapewireFind a company

person · Reporting owner

de los Pinos Elisabet

Disclosed activity across 1 company

Tapewire entity
63384
SEC CIK
0001889633

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aura Biosciences, Inc.AURA · Entity 5142Director · See RemarksMarch 02, 2026March 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aura Biosciences, Inc.

Report date March 02, 2026 · Filed March 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect575,815 Reported balance After 2026-03-02 transaction · row 1
1 source row

Row 1 · 2026-03-02 · Grant · Acquired 166,000 · Balance 575,815

F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2036-03-02Direct249,000 Reported balance After 2026-03-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-03-02 · Grant · Acquired 249,000 · Balance 249,000

F3: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Common StockSEC Table I · non-derivativeIndirectBy EdIP Revocable Trust127,763 Reported balance Holding disclosure · report date 2026-03-02 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 127,763

F2: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

F2: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

F3: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 02, 2026 Filed Mar 3, 2026 16:06 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantStock Option (Right to Buy) · Derivative 249,000 $0.00 Strike: $6.14 $0.00
Disclosure

SEC source: 0001193125-26-088162 · ownership.xml · derivative · entry 3

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 249,000

Underlying: Common Stock · 249,000 shares

Expires 2036-03-02

F3 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 16:06 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantCommon Stock 166,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-088162 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 575,815

F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

Read SEC document
February 17, 2026 Filed Feb 17, 2026 19:46 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 47,648 $5.06 $241,098.88
Disclosure

SEC source: 0001193125-26-055487 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 409,815

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 20, 2026 Filed Jan 20, 2026 18:41 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 16,928 $4.86 $82,270.08
Disclosure

SEC source: 0001193125-26-016938 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 457,463

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.73 to $4.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 29, 2025 Filed Oct 29, 2025 17:05 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 9,049 $6.35 $57,461.15
Disclosure

SEC source: 0001193125-25-256619 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 474,391

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 16:05 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 10,948 $0.00 Strike: $5.07 $0.00
Disclosure

SEC source: 0000950170-25-081615 · ownership.xml · derivative · entry 4

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,948 shares

Expires 2025-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These shares were acquired and/or withheld to cover the exercise price and resulting tax obligations, as applicable, in connection with a net (cashless) exercise of stock options. The stock options subject to the net exercise were to expire June 2, 2025. These transactions were completed subsequent to the execution of a Lock-Up Agreement and the shares received are subject to the provisions of that agreement.

F3 · derivative.exercise_date: This option is fully vested.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 16:05 UTC Aura Biosciences, Inc. AURA · Entity 5142 Tax withholdingCommon Stock 9,948 $6.16 $61,279.68
Disclosure

SEC source: 0000950170-25-081615 · ownership.xml · nonDerivative · entry 2

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 483,440

F1 · kind: These shares were acquired and/or withheld to cover the exercise price and resulting tax obligations, as applicable, in connection with a net (cashless) exercise of stock options. The stock options subject to the net exercise were to expire June 2, 2025. These transactions were completed subsequent to the execution of a Lock-Up Agreement and the shares received are subject to the provisions of that agreement.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 16:05 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 10,948 $5.07 $55,506.36
Disclosure

SEC source: 0000950170-25-081615 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 493,388

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These shares were acquired and/or withheld to cover the exercise price and resulting tax obligations, as applicable, in connection with a net (cashless) exercise of stock options. The stock options subject to the net exercise were to expire June 2, 2025. These transactions were completed subsequent to the execution of a Lock-Up Agreement and the shares received are subject to the provisions of that agreement.

Read SEC document
February 18, 2025 Filed Feb 18, 2025 19:30 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 20,221 $7.75 $156,795.66
Disclosure

SEC source: 0000950170-25-022651 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 482,440

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $8.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 17:52 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantStock Option (Right to Buy) · Derivative 255,680 $0.00 Strike: $7.68 $0.00
Disclosure

SEC source: 0000950170-25-013830 · ownership.xml · derivative · entry 3

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,680

Underlying: Common Stock · 255,680 shares

Expires 2035-02-02

F4 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 3, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 17:52 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantCommon Stock 194,320 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-013830 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 502,661

F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to the Reporting Person's continued service as of each such vesting date.

F2 · balance_after: On November 7, 2023, the Reporting Person filed a Form 4 which incorrectly included an additional 3,649 shares in the amount of securities beneficially owned directly after the reported transaction and excluded 3,649 shares from the amount of securities beneficially owned indirectly after the reported transaction. The Reporting Person's holdings after the transactions reported on this Form 4 reflect this correction.

Read SEC document
January 21, 2025 Filed Jan 21, 2025 21:09 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 15,955 $7.67 $122,381.23
Disclosure

SEC source: 0000950170-25-007495 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,692

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.67 to $7.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 29, 2024 Filed Oct 29, 2024 20:28 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 9,200 $10.74 $98,787.76
Disclosure

SEC source: 0000950170-24-118478 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,647

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 18, 2024 Filed Oct 18, 2024 20:08 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 24,992 $0.00 Strike: $2.74 $0.00
Disclosure

SEC source: 0000950170-24-115729 · ownership.xml · derivative · entry 4

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 336,171

Underlying: Common Stock · 24,992 shares

Expires 2028-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person.

F4 · derivative.exercise_date: This option is fully vested.

Read SEC document
October 18, 2024 Filed Oct 18, 2024 20:08 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 24,992 $12.04 $300,838.70
Disclosure

SEC source: 0000950170-24-115729 · ownership.xml · nonDerivative · entry 2

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 329,847

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 18, 2024 Filed Oct 18, 2024 20:08 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 24,992 $2.74 $68,478.08
Disclosure

SEC source: 0000950170-24-115729 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 354,839

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person.

Read SEC document
September 27, 2024 Filed Oct 1, 2024 17:08 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 5,474 $0.00 Strike: $5.76 $0.00
Disclosure

SEC source: 0000950170-24-110933 · ownership.xml · derivative · entry 3

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,474 shares

Expires 2024-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 27, 2024, the Reporting Person exercised long held stock options to purchase 5,474 shares of the Issuer's common stock, as they were set to expire on October 1, 2024.

F3 · derivative.exercise_date: This option is fully vested.

Read SEC document
September 27, 2024 Filed Oct 1, 2024 17:08 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 5,474 $5.76 $31,530.24
Disclosure

SEC source: 0000950170-24-110933 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 329,847

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 27, 2024, the Reporting Person exercised long held stock options to purchase 5,474 shares of the Issuer's common stock, as they were set to expire on October 1, 2024.

Read SEC document
February 01, 2024 Filed Feb 2, 2024 16:01 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantStock Option (Right to Buy) · Derivative 237,065 $0.00 Strike: $7.77 $0.00
Disclosure

SEC source: 0000950170-24-010460 · ownership.xml · derivative · entry 3

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 237,065

Underlying: Common Stock · 237,065 shares

Expires 2034-01-31

F3 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Read SEC document
February 01, 2024 Filed Feb 2, 2024 16:01 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantCommon Stock 162,935 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-010460 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 324,373

F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2025, subject to the Reporting Person's continued service as of each such vesting date.

Read SEC document
January 23, 2024 Filed Jan 24, 2024 16:20 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 15,853 $7.64 $121,140.70
Disclosure

SEC source: 0000950170-24-006988 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,438

F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.64 to $7.6758, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 06, 2023 Filed Nov 7, 2023 18:19 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionStock Option (Right to Buy) · Derivative 3,800 $0.00 Strike: $2.74 $0.00
Disclosure

SEC source: 0000950170-23-060499 · ownership.xml · derivative · entry 4

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 361,163

Underlying: Common Stock · 3,800 shares

Expires 2028-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person.

F4 · derivative.exercise_date: This option is fully vested.

Read SEC document
November 06, 2023 Filed Nov 7, 2023 18:19 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 7,449 $12.03 $89,610.73
Disclosure

SEC source: 0000950170-23-060499 · ownership.xml · nonDerivative · entry 2

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,291

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 06, 2023 Filed Nov 7, 2023 18:19 UTC Aura Biosciences, Inc. AURA · Entity 5142 Exercise / conversionCommon Stock 3,800 $2.74 $10,412.00
Disclosure

SEC source: 0000950170-23-060499 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 184,740

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 18:21 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 9,586 $6.83 $65,478.13
Disclosure

SEC source: 0000950170-23-057640 · ownership.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,940

F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.80 to $7.345, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 19, 2023 Filed Jan 23, 2023 18:35 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantStock Option (Right to Buy) · Derivative 187,500 Not disclosed Strike: $10.18 Not disclosed
Disclosure

SEC source: 0000899243-23-002434 · doc4.xml · derivative · entry 3

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 187,500 shares

Expires 2033-01-18

F3 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments.

F3 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments.

Read SEC document
January 19, 2023 Filed Jan 23, 2023 18:35 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantCommon Stock 121,875 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-002434 · doc4.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,526

F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.

Read SEC document
October 31, 2022 Filed Nov 2, 2022 20:37 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock 5,706 $12.46 $71,081.92
Disclosure

SEC source: 0000899243-22-034836 · doc4.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,651

F1 · kind: The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.45 to $12.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 02, 2021 Filed Nov 2, 2021 16:13 UTC Aura Biosciences, Inc. AURA · Entity 5142 ConversionSeries A-2 Preferred Stock · Derivative 1,510 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-042362 · doc4.xml · derivative · entry 4

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By EdIP Revocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 1,510 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.

F1 · price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.

F1 · derivative.exercise_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.

F1 · derivative.expiration_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.

F2 · ownership.nature: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

Read SEC document
November 02, 2021 Filed Nov 2, 2021 16:13 UTC Aura Biosciences, Inc. AURA · Entity 5142 ConversionSeries A-1 Preferred Stock · Derivative 3,042 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-042362 · doc4.xml · derivative · entry 3

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By EdIP Revocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 3,042 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.

F1 · price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.

F1 · derivative.exercise_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.

F1 · derivative.expiration_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.

F2 · ownership.nature: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

Read SEC document
November 02, 2021 Filed Nov 2, 2021 16:13 UTC Aura Biosciences, Inc. AURA · Entity 5142 ConversionCommon Stock 4,552 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-042362 · doc4.xml · nonDerivative · entry 2

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By EdIP Revocable Trust

Disclosed balance after: 131,412

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.

F2 · ownership.nature: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

Read SEC document
October 28, 2021 Filed Oct 29, 2021 19:28 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantStock Option (Right to Buy) · Derivative 318,750 Not disclosed Strike: $14.00 Not disclosed
Disclosure

SEC source: 0000899243-21-042090 · doc4.xml · derivative · entry 3

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,750

Underlying: Common stock · 318,750 shares

Expires 2031-10-27

F3 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2021 with the remainder vesting thereafter pro-rata in 36 monthly installments.

F3 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2021 with the remainder vesting thereafter pro-rata in 36 monthly installments.

Read SEC document
October 28, 2021 Filed Oct 29, 2021 19:28 UTC Aura Biosciences, Inc. AURA · Entity 5142 GrantCommon Stock 74,357 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-042090 · doc4.xml · nonDerivative · entry 1

de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,357

F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock. These restricted stock units vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.